BEGIN:VCALENDAR VERSION:2.0 METHOD:PUBLISH PRODID:-//Telerik Inc.//Sitefinity CMS 14.3//EN BEGIN:VTIMEZONE TZID:Arab Standard Time BEGIN:STANDARD DTSTART;VALUE=DATE:20230101 TZNAME:Arab Standard Time TZOFFSETFROM:+0300 TZOFFSETTO:+0300 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DESCRIPTION:Host: Professor Kyle LauersenAbstract: \;In\n this presenta tion\, Jan Schwarzhans will describe how during his career \nso far the ke y stakeholders have evolved from C. vulgaris to CEO\, what \nPharma looks like outside R&\;D and what the pros and cons \;of such a \ncareer path are.After completing his academic career with a \nPhD in Industrial B iotechnology\, he started his professional career in \nthe fast-paced worl d of Pharma Consulting at IQVIA. There he worked on \n40+ projects\, learn t a lot 'on the job' and advised Pharma clients on \nimportant business qu estions. Recently\, he joined the Investor Relations\n team at Roche. In h is new role\, Jan \;has a 'bird's-eye perspective' on \none of the lar gest Pharma's globally and \;supports senior management in \nthe prepa ration of quarterly reports and investor meetingsFor \neach career step\, examples\, key characteristics and learnings from the \nperspective of a P hD in Biotechnology will be detailed. We hope this \npresentation will pro vide students with insights into what a career \noutside academia or indus try R&\;D might look \;like.Bio: \;Jan-Philipp\n Schwarzhans (w ho goes by Jan) is an Investor Relations Officer at Roche\n in Basel\, Swi tzerland since July 2022. In his role\, Jan is focused on \nthe Roche Phar ma Group and is involved in preparing quarterly results \npresentations an d materials\, preparation of investor meetings\, \nassembling IR presentat ions for scientific conferences\, as well as \nengaging with Product/Franc hise leads to ensure accuracy and quality of \nIR materials.Jan joined Roc he from IQVIA\, a leading global provider\n of advanced analytics\, techno logy solutions and clinical research \nservices to the life sciences indus try. For the period of four years\, \nJan was part of the Strategy &\; Life Sciences Consulting group\, \nadvising Pharma and Biotech clients on Brand &\; Commercial Strategy\, \nLaunch Excellence\, Pricing &\; Ma rket Access\, Forecasting and Customer\n Engagements projects. His project s spanned US\, Europe\, APAC and MEA \nmarkets\, with a focus on Oncology\ , Rare Diseases\, Cardiovascular and \nDiabetes indications. Simultaneousl y\, he completed a 1.5 year secondment\n in the IQVIA Thought Leadership t eam\, working on analyzing and \npresenting the 'big picture' Pharma trend s for senior client audiences.He holds a PhD in Industrial Biotechnology f rom the Center for \nBiotechnology at Bielefeld University\, Germany. Whil e his PhD focused on\n optimizing protein expression in the yeast Pichia p astoris\, his \nBachelor and Master thesis dealt with different Algal biot echnology \ntopics. Jan has published multiple research papers in the fiel d of \nmicrobiotechnology and is highly interested in following recent \ns cientific developments DTEND:20230308T110000Z DTSTAMP:20240329T140432Z DTSTART:20230308T100000Z LOCATION:Zoom SEQUENCE:0 SUMMARY:Beyond R&D: Post-PhD career paths in Consulting and Pharma UID:RFCALITEM638473286728823593 X-ALT-DESC;FMTTYPE=text/html:
Host: Professor Kyle Lauer
sen
Abstract: \;
In\n this presentation\
, Jan Schwarzhans will describe how during his career \nso far the key sta
keholders have evolved from C. vulgaris to CEO\, what \nPharma looks like
outside R&\;D and what the pros and cons \;of such a \ncareer path
are.
After completing his academic career with a \nPhD in Indust rial Biotechnology\, he started his professional career in \nthe fast-pace d world of Pharma Consulting at IQVIA. There he worked on \n40+ projects\, learnt a lot 'on the job' and advised Pharma clients on \nimportant busin ess questions. Recently\, he joined the Investor Relations\n team at Roche . In his new role\, Jan \;has a 'bird's-eye perspective' on \none of t he largest Pharma's globally and \;supports senior management in \nthe preparation of quarterly reports and investor meetings
For \neach c
areer step\, examples\, key characteristics and learnings from the \npersp
ective of a PhD in Biotechnology will be detailed. We hope this \npresenta
tion will provide students with insights into what a career \noutside acad
emia or industry R&\;D might look \;like.
Bio:&nb
sp\;
Jan-Philipp\n Schwarzhans (who goes by Jan) is an Investo
r Relations Officer at Roche\n in Basel\, Switzerland since July 2022. In
his role\, Jan is focused on \nthe Roche Pharma Group and is involved in p
reparing quarterly results \npresentations and materials\, preparation of
investor meetings\, \nassembling IR presentations for scientific conferenc
es\, as well as \nengaging with Product/Franchise leads to ensure accuracy
and quality of \nIR materials.
Jan joined Roche from IQVIA\, a leading
global provider\n of advanced analytics\, technology solutions and clinic
al research \nservices to the life sciences industry. For the period of fo
ur years\, \nJan was part of the Strategy &\; Life Sciences Consulting
group\, \nadvising Pharma and Biotech clients on Brand &\; Commercial S
trategy\, \nLaunch Excellence\, Pricing &\; Market Access\, Forecasting
and Customer\n Engagements projects. His projects spanned US\, Europe\, A
PAC and MEA \nmarkets\, with a focus on Oncology\, Rare Diseases\, Cardiov
ascular and \nDiabetes indications. Simultaneously\, he completed a 1.5 ye
ar secondment\n in the IQVIA Thought Leadership team\, working on analyzin
g and \npresenting the 'big picture' Pharma trends for senior client audie
nces.
He holds a PhD in Industrial Biotechnology from the Center for \n
Biotechnology at Bielefeld University\, Germany. While his PhD focused on\
n optimizing protein expression in the yeast Pichia pastoris\, his \nBache
lor and Master thesis dealt with different Algal biotechnology \ntopics. J
an has published multiple research papers in the field of \nmicrobiotechno
logy and is highly interested in following recent \nscientific development
s